Bicocca Open Archive

Logo unimib boa

Frustaci, A., Montillo, M., Rossi, D., Zinzani, P., Motta, M., Gaidano, G., et al. (2023). Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome. In Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) (pp.7502-7502). American Society of Clinical Oncology [10.1200/JCO.2023.41.16_suppl.7502].

Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome

Cairoli, Roberto;
2023
abstract
Richter, CLL; Richter Syndrome
English
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) JUN 02-06, 2023
2023
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
31-mag-2023
2023
41
16 Suppl
7502
7502
7502
none
Frustaci, A., Montillo, M., Rossi, D., Zinzani, P., Motta, M., Gaidano, G., et al. (2023). Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome. In Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) (pp.7502-7502). American Society of Clinical Oncology [10.1200/JCO.2023.41.16_suppl.7502].
02 - Intervento a convegno
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/451408
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 3
Social impact